BPC-157 research peptide vial — pentadecapeptide from body protective compound, ≥99% HPLC purity, sold in Canada for laboratory research use.

What is BPC-157? A Complete Guide to the Pentadecapeptide

BPC-157 has become one of the most-studied research peptides in modern recovery and tissue repair research. With over 100 published animal studies spanning gastrointestinal, musculoskeletal, vascular, and neural research domains, BPC-157 has accumulated an unusually deep evidence base for a research compound that hasn't yet progressed through extensive clinical-stage human trials. For Canadian laboratories working with this compound — and anyone trying to understand what makes it pharmacologically distinct — the answer requires understanding what BPC-157 is, where it comes from, and how it works at the molecular level.

This guide explains what BPC-157 is in comprehensive detail, covering its origin in body protective compound, molecular structure, mechanism of action, research applications, and sourcing considerations for Canadian labs. Our complete BPC-157 research peptide catalog ships at ≥99% HPLC purity with mass-spec-verified identity and fast domestic Canadian shipping.

The short version: BPC-157 is a synthetic 15-amino-acid pentadecapeptide derived from a partial sequence of body protective compound (BPC), originally isolated from human gastric juice. The compound operates through two complementary molecular mechanisms — nitric oxide pathway modulation and VEGFR2-mediated angiogenesis — that together produce cytoprotective and tissue-repair-supporting effects across an unusually broad range of injury models. The long version covers the discovery, pharmacology, and research context in depth.

Table of Contents

What is BPC-157? Definition and Overview

BPC-157 is a synthetic 15-amino-acid peptide — a pentadecapeptide — derived from a partial sequence of body protective compound (BPC), an endogenous protective peptide originally isolated from human gastric juice. The compound has the amino acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.

Several features make BPC-157 pharmacologically distinct from other research peptides:

Gastric juice origin. BPC-157 derives from a peptide naturally produced by the human body in gastric juice, where it appears to function as part of an endogenous protective mechanism. The synthetic version makes laboratory research possible across a much broader range of injury models than gastric juice alone could support.

Cytoprotective activity. The defining biological feature of BPC-157 is cytoprotection — protecting cells and tissues from damage across multiple types of injury. This isn't a narrow effect on one tissue type; it's a broad protective response that appears across gastrointestinal, musculoskeletal, vascular, neural, and other systems.

Unusual stability. BPC-157 is stable in gastric juice without requiring a carrier protein — an unusual property for a peptide. This stability reflects its origin and gives the compound experimental flexibility that most research peptides don't have.

Extensive preclinical evidence. With over 100 published animal studies, BPC-157 has one of the deepest preclinical literature bases in the research peptide category. This evidence breadth supports its use as a reference compound across many research domains.

The compound is widely used in recovery research, tissue repair studies, and broader cytoprotection research designs. Researchers select BPC-157 when they need a tool that operates through nitric oxide and angiogenic pathways with documented activity across multiple tissue types.

BPC-157 Discovery and Origin

Understanding what BPC-157 is requires understanding where it comes from. The compound's discovery and development tell a coherent story about endogenous protective mechanisms in the human body.

Discovery of Body Protective Compound (BPC)

The story begins with Predrag Sikiric and colleagues at the University of Zagreb School of Medicine in Croatia, in the late 1980s and early 1990s.The research group was investigating compounds with cytoprotective activity in gastrointestinal injury models when they identified a protective factor in human gastric juice that could prevent damage in various injury contexts.

This protective factor — body protective compound, or BPC — appeared to be the body's own response to digestive stress. The gastric environment is harsh: highly acidic conditions, mechanical stress from peristalsis, and constant exposure to potentially damaging substances. The presence of an endogenous protective peptide in this environment made biological sense.

Identification of the Active 15-Amino-Acid Fragment

Once BPC was identified, Sikiric's group worked to determine which portion of the molecule was responsible for the protective activity. Through systematic studies, they identified a 15-amino-acid fragment that retained the full cytoprotective activity of the parent BPC molecule. This fragment became known as BPC-157.

The naming convention reflects the discovery — "BPC" for body protective compound and "157" indicating the specific 15-amino-acid sequence that had the protective activity. This fragment proved to be more practical to synthesize and study than the full BPC molecule, making it the standard research tool in subsequent investigations.

Why BPC-157 Specifically Matters

The 15-amino-acid sequence has several specific characteristics that distinguish it:

  • Manageable size for chemical synthesis using standard solid-phase peptide synthesis methods
  • Retention of full biological activity despite being shorter than the parent molecule
  • Stability characteristics that allow it to remain functional in various biological environments
  • Defined chemical structure that supports reproducible research across laboratories

These properties together explain why BPC-157, rather than the parent BPC, became the standard research compound. It's pragmatic — easier to make, easier to study, retains the relevant biology.

Continued Development Since Discovery

Since the initial identification, BPC-157 research has continued to expand. Multiple research groups around the world have studied the compound across an increasing range of injury models and tissue types. The breadth of published literature on BPC-157 today substantially exceeds what existed at the time of its initial characterization.

The compound has not progressed to substantial clinical-stage human trials, which is a meaningful gap in its evidence base. Its current research status remains preclinical, though the depth of animal-model evidence is unusual for a compound at this stage.

BPC-157 Molecular Structure

What is BPC-157 at the molecular level? Understanding the structure helps clarify the compound's biological activity.

The 15-Amino-Acid Sequence

BPC-157 consists of 15 amino acids in the sequence:

Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

Key structural features:

  • Multiple proline residues: The four proline residues in the sequence contribute to the peptide's stability and resistance to proteolytic degradation. Proline-rich peptides typically resist degradation better than peptides without these residues.
  • No disulfide bonds: Unlike some peptides that depend on disulfide bonds for activity, BPC-157 is a linear peptide without these cross-links.
  • Mixed charge profile: The peptide contains both positively charged (lysine) and negatively charged (glutamic acid, aspartic acid) residues, contributing to its solubility properties.
  • Molecular weight: Approximately 1,419 daltons — a small molecular weight that allows the peptide to access many tissue compartments.

Synthesis Considerations

Modern BPC-157 is produced through solid-phase peptide synthesis, the standard method for manufacturing synthetic peptides of this size. The synthesis involves:

  • Sequential amino acid coupling to a solid support
  • Protection and deprotection steps to ensure correct amino acid sequence
  • Cleavage from the solid support to produce the free peptide
  • Purification through high-performance liquid chromatography
  • Identity verification through mass spectrometry

Research-grade BPC-157 should be ≥99% pure by HPLC, with mass spectrometry confirming the molecular weight matches the theoretical value of approximately 1,419 daltons. Both metrics should appear on the certificate of analysis for any specific batch.

Storage Stability

BPC-157's structure contributes to relatively favorable storage stability for a research peptide. The lyophilized form is stable for 12+ months at refrigerator temperatures (2-8°C) and 24+ months at freezer temperatures (-20°C) when protected from light. For more detail on BPC-157 storage best practices, see How to Store Research Peptides: A Complete Stability and Handling Guide.

How Does BPC-157 Work? Mechanism of Action

The most important question for research design: how does BPC-157 produce its biological effects?

BPC-157's mechanism of action centers on two complementary molecular pathways that work together to produce cytoprotective and tissue-repair-supporting effects.

Nitric Oxide (NO) Pathway Modulation

BPC-157 interacts with the nitric oxide signaling pathway, increasing NO availability through effects on endothelial nitric oxide synthase (eNOS) and related signaling components.

Nitric oxide has several biological effects relevant to tissue repair:

  • Vasodilation: NO relaxes blood vessel smooth muscle, improving blood flow to tissues
  • Anti-inflammatory activity: NO modulates inflammatory cytokines and reduces excessive inflammation
  • Cytoprotection: NO protects cells from oxidative damage and apoptosis
  • Anti-platelet effects: NO prevents excessive blood clotting that could compromise tissue perfusion

By increasing NO availability, BPC-157 supports the early-phase tissue response to injury — improved blood flow, reduced inflammation, and protected cellular survival.

VEGFR2-Mediated Angiogenesis

BPC-157 upregulates vascular endothelial growth factor receptor 2 (VEGFR2) expression and signaling. VEGFR2 is the primary receptor driving angiogenesis — the formation of new blood vessels.

The angiogenic activity supports tissue repair through:

  • New blood vessel formation: Damaged tissue requires new vasculature to support recovery
  • Improved nutrient and oxygen delivery: Repaired tissue needs adequate blood supply to function
  • Cellular signaling support: VEGFR2 signaling extends beyond vessel formation to broader cellular activity

The angiogenic activity is particularly important in research designs investigating chronic wounds, ischemic injury, and conditions where vascular insufficiency contributes to poor healing outcomes.

The Two Pathways Work Together

BPC-157's biological activity comes from the synergy between these two mechanisms:

  • NO pathway effects improve immediate blood flow and provide acute cytoprotection
  • VEGFR2 effects support the longer-term vascular remodeling needed for sustained repair

The combination produces both immediate and sustained tissue support, which helps explain why BPC-157 shows effects across such a wide range of injury models. The mechanism isn't tissue-specific — both NO signaling and VEGFR2-mediated angiogenesis are relevant to virtually any tissue type undergoing repair.

For deeper comparison of how BPC-157's mechanism differs from other recovery peptides, see BPC-157 vs TB-500: A Complete Research Peptide Comparison Guide.

Additional Molecular Effects

Beyond the two primary mechanisms, BPC-157 has documented effects on:

  • Growth hormone receptor signaling: Modulation of GH receptor expression in muscle and tendon tissue
  • Dopaminergic signaling: Effects on dopamine pathways relevant to neural research applications
  • Serotonergic signaling: Effects on serotonin pathways relevant to gastrointestinal and neural research
  • Anti-ulcer activity: Direct cytoprotective effects in gastric mucosa

These additional effects help explain BPC-157's breadth across research applications. The compound isn't operating through a single narrow mechanism — it engages multiple complementary biological pathways.

Unique Properties of BPC-157

Three properties distinguish BPC-157 from most other research peptides and make it particularly valuable as a research tool.

Gastric Stability

BPC-157 remains stable in gastric juice without requiring a carrier protein or protective formulation. Most peptides break down rapidly in the harsh gastric environment — the low pH, presence of pepsin, and other digestive enzymes typically destroy peptides within minutes.

BPC-157's gastric stability reflects its origin as a fragment of an endogenous gastric peptide. The body evolved this compound to function in exactly this environment, so the synthetic version retains the same stability properties.

This stability has important research implications:

  • Oral administration studies are possible without requiring elaborate protective formulations
  • Gastrointestinal research applications can use the compound directly in gastric or intestinal contexts
  • Experimental flexibility allows researchers to investigate the compound across different administration routes

Broad Tissue Activity

BPC-157's published evidence base spans an unusually wide range of injury models and tissue types. The compound has documented activity in:

  • Gastrointestinal injury (multiple models)
  • Tendon and ligament repair
  • Muscle injury and recovery
  • Cardiac and vascular research
  • Neural and central nervous system models
  • Dermal and wound healing
  • Inflammatory bowel disease models
  • Various ischemia-reperfusion models

This breadth is unusual. Most research peptides have stronger evidence in some tissue types than others. BPC-157's evidence depth is comparable across many domains, supporting its use as a reference compound for cross-tissue research designs.

Endogenous Origin

BPC-157's status as a fragment of an endogenous human peptide gives it different research significance than purely synthetic compounds. The body already produces the parent BPC molecule as part of natural protective mechanisms — synthetic BPC-157 isn't introducing a foreign molecule, it's mimicking an endogenous protective response.

This endogenous origin contributes to:

  • Research relevance: Studies on BPC-157 inform understanding of natural protective mechanisms
  • Receptor and pathway integration: The compound interacts with biological systems evolved to recognize it
  • Mechanism research: Studying BPC-157 helps researchers understand how the body's own protective responses work

BPC-157 Research Applications

Given BPC-157's mechanism and evidence base, which research applications benefit most from this compound?

Gastrointestinal Research

BPC-157 has the deepest evidence base in gastrointestinal research, reflecting its origin in gastric juice. Research applications include:

  • NSAID-induced gastric injury models: BPC-157 has documented cytoprotective effects against the gastric damage produced by non-steroidal anti-inflammatory drugs
  • Inflammatory bowel disease models: Crohn's disease and ulcerative colitis research designs have used BPC-157 as a tool to investigate inflammatory mechanisms
  • Esophageal injury research: Including studies of esophageal anastomosis and burn injury models
  • General gastric mucosal protection research: Acute and chronic models of gastric damage

The combination of BPC-157's gastric origin, gastric stability, and demonstrated activity in GI models makes this its strongest research application area.

Musculoskeletal Repair Research

The second-largest research application is musculoskeletal repair:

  • Tendon injury research: Achilles tendon transection models are particularly well-studied with BPC-157
  • Ligament repair: Medial collateral ligament studies have documented improved healing parameters
  • Muscle injury models: Crush injury and other muscle damage research designs

The angiogenic and cytoprotective mechanisms support repair processes in connective tissue specifically, making BPC-157 a natural fit for musculoskeletal research.

Vascular and Cardiovascular Research

BPC-157's effects on the NO pathway and VEGFR2 signaling make it directly relevant to vascular research:

  • Ischemia-reperfusion injury models: Including cardiac and other organ-specific applications
  • Angiogenesis research: Both basic biology and therapeutic applications
  • Endothelial function research: NO pathway studies

Neurological Research

A growing body of research has examined BPC-157 in neurological contexts:

  • Traumatic brain injury models
  • Ischemic stroke research
  • Peripheral nerve injury and regeneration
  • Spinal cord injury studies

The compound's cytoprotective and vascular effects translate to neuroprotective applications in these designs.

For comprehensive coverage of compound selection across the recovery research category, see Best Peptides for Recovery and Healing Research: A Comparison Guide for Canadian Labs.

Inflammatory Disease Research

BPC-157's anti-inflammatory activity through NO pathway modulation has supported research designs investigating:

  • Chronic inflammatory conditions
  • Cytokine modulation research
  • Autoimmune disease models

Published Evidence Base for BPC-157

The depth of published BPC-157 research is one of the compound's defining characteristics. The full body of research is searchable through PubMed, the U.S. National Library of Medicine's authoritative database of peer-reviewed biomedical literature. Understanding this evidence base helps researchers contextualize what BPC-157 can and can't claim.

Breadth of Published Research

BPC-157 has accumulated more than 100 published animal studies across multiple research domains. The literature is searchable through PubMed's BPC-157 search, which provides access to the full corpus of peer-reviewed publications.

The publications span:

  • Multiple model species (rats, mice, larger animal models)
  • Multiple injury types (mechanical, chemical, ischemic, inflammatory)
  • Multiple tissue systems (every major organ system)
  • Multiple research groups (Croatian and international research teams)

This breadth represents an unusually deep preclinical foundation for a research compound.

Quality of Published Research

The published BPC-157 literature has been examined by both supporters and critics. Important characteristics:

Strong points:

  • Multiple independent research groups have replicated key findings
  • Studies span peer-reviewed journals across multiple disciplines
  • Many studies include rigorous experimental controls
  • The mechanism (NO/VEGFR2) is well-characterized through molecular studies

Limitations to acknowledge:

  • The majority of high-impact BPC-157 publications come from one primary research center (Sikiric and colleagues at the University of Zagreb)
  • Independent replication outside this group, while present, is more limited
  • Clinical-stage human trials are limited compared to the preclinical depth
  • Some critics have noted that the breadth of claimed effects warrants additional scrutiny

The research community generally accepts BPC-157 as a legitimate research compound with documented activity, while also recognizing that the clinical evidence base is less developed than the preclinical evidence might suggest.

Limitations of Current Evidence

For research designs and informed buyers, the current BPC-157 evidence has these limitations:

  • Limited human clinical data: Most studies are in animal models
  • Variable methodology across studies: Different research groups use different protocols
  • Limited dose-response characterization: Compared to clinically-developed compounds
  • Long-term safety data: Limited information on chronic administration effects

These limitations don't invalidate the research interest in BPC-157, but they should inform how researchers interpret the available evidence.

How BPC-157 Compares to Other Recovery Peptides {#bpc-157-comparison}

BPC-157 occupies a specific position in the broader landscape of recovery research peptides.

BPC-157 vs TB-500

The most common direct comparison is with TB-500 (synthetic thymosin β-4). The two compounds work through entirely different mechanisms:

  • BPC-157: NO pathway and VEGFR2-mediated angiogenesis
  • TB-500: G-actin sequestration and cytoskeletal regulation

This mechanism non-overlap makes them complementary rather than substitutes. Many research designs use both compounds together, particularly in the BPC-157 and TB-500 stack format known as the Wolverine Stack.

For complete comparison, see BPC-157 vs TB-500: A Complete Research Peptide Comparison Guide.

BPC-157 vs GHK-Cu

GHK-Cu (copper tripeptide) has different applications than BPC-157:

  • BPC-157: Strongest in GI, musculoskeletal, and vascular research
  • GHK-Cu: Strongest in skin, hair, and ECM remodeling research

The compounds can be combined for research designs investigating multi-mechanism repair, particularly in the Glow Stack format.

BPC-157 vs Tesamorelin

Tesamorelin operates through a completely different pathway (GHRH/IGF-1 axis) than BPC-157. The two compounds aren't substitutes — they address fundamentally different research questions:

  • BPC-157: Direct cytoprotective and angiogenic effects on tissue
  • Tesamorelin: Systemic GH/IGF-1 axis activation with downstream effects

Research designs investigating recovery in the context of GH-axis biology might use both compounds for different aspects of the research.

Sourcing BPC-157 for Canadian Research

When sourcing BPC-157 for Canadian research, four sourcing criteria distinguish quality suppliers from problematic ones.

HPLC purity verification. Research-grade BPC-157 should be ≥99% pure as measured by high-performance liquid chromatography. The compound is well-established and ≥99% purity is achievable at scale, but not all suppliers actually verify this on every batch. Demand batch-specific HPLC documentation, not generic certificates.

Mass spectrometry identity confirmation. HPLC measures purity but not identity. Mass spectrometry verifies that the molecular weight matches the theoretical value of approximately 1,419 daltons. Both metrics should appear on the certificate of analysis for any specific vial.

Batch-specific certificates of analysis. Generic certificates that don't reference specific batch numbers provide no quality assurance. Quality suppliers provide COAs traceable to specific manufacturing lots — the lot number on the vial should match the lot number on the COA.

Domestic Canadian supply chain. Lyophilized peptides are sensitive to thermal cycling during shipping. Domestic Canadian shipping eliminates the cold-chain variables that compromise international shipments. For more on supplier evaluation criteria, see Emerald Peptides vs. Other Brands: 7 Standards That Separate Quality Research Peptide Suppliers.

For comprehensive guidance on buying research peptides in Canada — including the full quality framework, sourcing considerations, and supplier evaluation — see The Complete Research Peptides Canada Buying Guide for 2026.

Emerald Peptides supplies BPC-157 research peptide at ≥99% HPLC purity with fast domestic Canadian shipping.

Frequently Asked Questions

What is BPC-157 used for in research?

BPC-157 is used in research designs investigating tissue repair, cytoprotection, angiogenesis, and related biological processes. The compound has documented activity across multiple injury models and tissue types — gastrointestinal injury, tendon and ligament repair, muscle damage, vascular research, and neurological research. Research applications include studying the mechanisms of tissue repair, investigating cytoprotective pathways, and comparing repair processes across different tissue systems. The compound is sold strictly for laboratory research use only and is not approved for human consumption.

What does BPC-157 stand for?

BPC-157 stands for "Body Protective Compound 157." The "BPC" portion refers to body protective compound, the parent peptide originally isolated from human gastric juice. The "157" indicates the specific 15-amino-acid fragment of BPC that retains the full cytoprotective activity of the parent molecule. The naming convention reflects both the compound's origin (body protective compound) and its specific structural identity (the 15-amino-acid sequence within BPC).

How does BPC-157 work?

BPC-157 operates through two complementary molecular mechanisms that together produce cytoprotective and repair-supporting effects. First, the compound modulates the nitric oxide (NO) pathway, increasing NO availability through effects on endothelial nitric oxide synthase. This produces vasodilation, anti-inflammatory effects, and direct cytoprotection. Second, BPC-157 upregulates vascular endothelial growth factor receptor 2 (VEGFR2) signaling, driving the formation of new blood vessels at injury sites. The combination of improved blood flow (NO pathway) and new vascular network formation (VEGFR2) supports tissue repair across multiple injury contexts.

What is the difference between BPC and BPC-157?

BPC (body protective compound) is the parent molecule originally isolated from human gastric juice. BPC-157 is a 15-amino-acid fragment of BPC that retains the full cytoprotective activity of the parent molecule. The relationship is similar to how some hormone fragments (like HGH Fragment 176-191) retain specific activities from larger parent molecules. BPC-157 became the standard research compound because it's more practical to synthesize than the full BPC molecule while retaining the same biological activity.

Where does BPC-157 come from?

BPC-157 originates from body protective compound (BPC), a peptide originally isolated from human gastric juice. The parent BPC molecule appears to function as part of the body's endogenous protective response to digestive stress. BPC-157 represents a 15-amino-acid fragment of this parent molecule that retains the full cytoprotective activity. The compound was first identified and characterized by Predrag Sikiric and colleagues at the University of Zagreb, Croatia, in the late 1980s and early 1990s. Modern research-grade BPC-157 is produced through solid-phase peptide synthesis rather than isolated from biological sources.

What is the difference between BPC-157 and TB-500?

BPC-157 and TB-500 are two of the most commonly compared recovery research peptides, but they operate through entirely different molecular mechanisms. BPC-157 is a 15-amino-acid peptide derived from gastric juice that works through nitric oxide signaling and VEGFR2-mediated angiogenesis. TB-500 is a 43-amino-acid synthetic version of thymosin β-4 that works through G-actin sequestration and actin cytoskeleton regulation. The two compounds target different pathways and are often used together in research designs for parallel-pathway investigation. See our BPC-157 vs TB-500 comparison post for complete detail.

Where can I buy BPC-157 in Canada?

Canadian research labs sourcing BPC-157 should look for suppliers meeting three criteria: ≥99% HPLC purity confirmation on every batch, mass spectrometry verification of identity, and domestic Canadian shipping to eliminate cold-chain interruption variables. Emerald Peptides supplies BPC-157 research peptide for research use only, with batch-specific certificates of analysis, MS-verified identity, and fast domestic Canadian shipping. For research designs combining BPC-157 with TB-500, the Wolverine Stack provides both compounds in a matched-batch format. For broader supplier evaluation criteria, see our Emerald Peptides vs. Other Brands post.

⚠️ For research use only. Not intended for human or veterinary use. Not a drug, food, or supplement.

Back to blog